

| Quality assessment | | | | | | | No of patients | | Effect | | Quality Importance |
|--|-------------------|----------------------|--------------------------|----------------------|------------------------|----------------------|----------------|--------------|------------------------|--|--------------------|
| No of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Intervention | Control | Relative (95% CI) | Absolute | |
| HPV vaccine initiation (follow-up up to 9 months) | | | | | | | | | | | |
| 2 ^a | randomised trials | serious ¹ | no serious inconsistency | serious ² | no serious imprecision | none | 48/148 (32.4%) | 24/150 (16%) | RR 1.92 (1.27 to 2.91) | 147 more per 1000 (from 43 more to 306 more) | LOW |

^a Bass 2021, Reiter 2018

¹ Downgraded for some concerns of bias due to no information on allocation concealment for Bass 2021, and no information on randomisation or allocation concealment for Reiter 2012

² US studies